You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Government & Policy Articles
Popular Government & Policy Articles
Highly Recommended Government & Policy Articles
Glumetza
Glumetza, a once-daily extended-release formulation of metformin hydrochloride, was granted FDA approval in June 2005 for the treatment of type 2 diabetes.
According to Biovail, the drug’s manufacturer, Glumetza “may offer potential advantages such as less frequent dosing and proven effectiveness in combination with other diabetes drugs.” In addition, they say that Glumetza offers “excellent tolerability that allows physicians to more quickly administer a high enough dose to provide [blood glucose] control without significantly increasing the incidence of nausea, diarrhea and other side effects that are sometimes caused by metformin products.”
Glumetza is not recommend for people with kidney problems, heart failure that is treated with medicine, or diabetic ketoacidosis. The most common side effects of Glumetza include diarrhea, nausea and upset stomach. Glumetza can also cause lactic acidosis.
Source: Biovail Corp.
Categories: Blood Glucose, Diabetes, Diabetes, Government & Policy, Medications, Metformin, Type 2 Issues, Type 2 Medications
0 comments -
Dec 1, 2005
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.




Email to a Friend
Send a link to this page to your friends and colleagues.